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Background: Therapy fidelity monitoring is essential in trial evaluations. However, previous 
adherence to a trial protocol investigating the effect of 28 hours of intensive, early aphasia 
therapy, was low (29%) and feasibility of adherence reported as ‘improbable’. VERSE is a 
PROBE trial, to determine whether two types of intensive aphasia therapy within 14 days of 
acute stroke, provided for 20 sessions (minimum 15 hours), deliver greater efficacy and cost-
effectiveness than usual care with particular attention paid to monitoring of trial fidelity. 
Methods: Eligible participants with acute post-stroke aphasia are stratified by aphasia severity and 
randomised to receive usual care, usual care-plus (usual ward based therapy provided daily) or 
VERSE therapy (a prescribed aphasia therapy provided daily)(N = 246). Therapy adherence is 
independently monitored with feedback provided to therapists following analysis of video 
recordings. The primary outcome is the Aphasia Quotient of the Western Aphasia Battery at 
three months. Secondary outcomes include resource use, quality-of-life and depression 
measures. 
Results: 15 sites are recruiting. Of 6246 people with stroke 1575 (25%) had aphasia and 325 (20%) 
were trial eligible. 172 (53%) have been recruited. Monitoring of all therapy sessions and 259 
video-recorded sessions indicates treatment adherence is 90% and treatment differentiation is 
100%. 
Discussion: Clinical trials reported without reference to treatment fidelity risk serious 
misinterpretation of outcomes. Our rigorous therapy fidelity processes demonstrate that early 
intensive aphasia therapy can be consistently provided at intense levels. With high levels of 
therapy fidelity, these data will contribute substantially to the early aphasia therapy debate.
